Mads Krogsgaard Thomsen/LinkedIn
Dec 16, 2025, 16:34
Mads Krogsgaard Thomsen on Novo Nordisk Haemophilia Foundation’s Support for Haemoglobinopathies
Mads Krogsgaard Thomsen, CEO at Novo Nordisk Foundation, shared on LinkedIn:
”Haemophilia and other blood disorders like sickle cell disease and thalasaemia are chronic, debilitating diseases.
As is often the case, global health inequity is very pronounced, with under-diagnosis, under-treament and poor outcomes as a result in many low and middle income countries.
It is therefore a pleasure to announce that Novo Nordisk Foundation is stepping up, both in absolute funding terms, and in adding the haemoglobinopathy disorders to our support to the Novo Nordisk Haemophilia and Haemoglobinopathies Foundation in these areas.”
Read the full announcement here.
Stay updated with Hemostasis Today.
-
Jul 13, 2026, 11:25Luisa Müller: Advancing Anticoagulation Strategies for VITT at ISTH 2026
-
Jul 13, 2026, 10:49Joshua Zeidner: Advancing Menin Inhibitor Therapy in MD Education AML-ALL US Focus 2026
-
Jul 13, 2026, 10:25Flora Peyvandi: A Practical Approach to ALT Elevation After Gene Therapy at ISTH 2026
-
Jul 13, 2026, 10:02Jessica Garcia: Where Science and Community Come Together at ISTH 2026
-
Jul 13, 2026, 09:46Fabrice Cognasse: Is There Such a Thing as the Perfect Platelet Product?
-
Jul 13, 2026, 09:42Cancer-Associated Arterial Thromboembolism: Redefining the Thrombotic Burden in Oncology
-
Jul 13, 2026, 05:59Connecting and Collaborating at ISTH 2026 – NNHF
-
Jul 13, 2026, 05:58Lara Monica: Back at ISTH – Looking Forward to Science and Reconnections!
-
Jul 13, 2026, 05:57Barbara Adams Krolak: Exciting Updates From the ISTH 2026 Regulatory Session